Linked Data API

Show Search Form

Search Results

100885
registered interest false more like this
date less than 2014-10-24more like thismore than 2014-10-24
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Asthma: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211885 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
remove maximum value filtermore like thismore than 2014-10-29T17:12:29.113Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100887
registered interest false more like this
date less than 2014-10-24more like thismore than 2014-10-24
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Asthma more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211918 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100721
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Osteoporosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211732 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100723
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Motor Neurone Disease: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211734 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100728
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Motor Neurone Disease more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211730 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100730
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Osteoporosis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211735 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100186
registered interest false more like this
date less than 2014-10-21more like thismore than 2014-10-21
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Patients: Safety more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events. more like this
tabling member constituency Oxford East more like this
tabling member printed
Mr Andrew Smith more like this
uin 211233 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-28more like thismore than 2014-10-28
answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-28T15:28:25.797Zmore like thismore than 2014-10-28T15:28:25.797Z
question first ministerially corrected
less than 2014-10-28T16:30:53.2329022Zmore like thismore than 2014-10-28T16:30:53.2329022Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
24770
answering member constituency Battersea more like this
answering member printed Jane Ellison more like this
answering member 3918
tabling member
95
label Biography information for Mr Andrew Smith more like this
92843
registered interest false more like this
date less than 2014-10-13more like thismore than 2014-10-13
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading General Practitioners more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how many GPs working in the NHS aged (a) 25 to 35, (b) 35 to 45, (c) 45 to 55 and (d) 55 to 65 years old are (i) male and (ii) female. more like this
tabling member constituency Vale of Clwyd more like this
tabling member printed
Chris Ruane more like this
uin 210052 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-20more like thismore than 2014-10-20
answer text <p>The Health and Social Care Information Centre General and Personal Medical Services workforce census shows the number of general practitioners (GPs) by age band and gender working in the NHS in England as at 30 September each year.</p><p> </p><p> </p><p> </p><p>The attached table shows the number of GPs (excluding registrars and retainers) but including GP providers (partners) and GP others (salaried) by age band and gender as at 30 September 2013 working in the NHS in England.</p><p> </p> more like this
answering member constituency Central Suffolk and North Ipswich more like this
answering member printed Dr Daniel Poulter more like this
question first answered
less than 2014-10-20T16:41:38.003Zmore like thismore than 2014-10-20T16:41:38.003Z
question first ministerially corrected
less than 2014-10-20T16:54:36.8350775Zmore like thismore than 2014-10-20T16:54:36.8350775Z
answering member
3932
label Biography information for Dr Dan Poulter more like this
attachment
1
file name PQ210052 GPs by age band.xlsx more like this
title GPs by Age Band Sept 2013 more like this
previous answer version
23112
answering member constituency Central Suffolk and North Ipswich more like this
answering member printed Dr Daniel Poulter more like this
answering member
3932
label Biography information for Dr Dan Poulter more like this
tabling member
534
label Biography information for Chris Ruane more like this
92595
registered interest false more like this
date less than 2014-10-10more like thismore than 2014-10-10
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Medical Records: Databases more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what assessment he has made of the potential benefits to the NHS of increasing the extent to which patient-level data is shared between organisations; and if he will make a statement. more like this
tabling member constituency Sutton and Cheam more like this
tabling member printed
Paul Burstow more like this
uin 209873 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-17more like thismore than 2014-10-17
answer text <p>Effective sharing of patient information between organisations as part of a person’s direct care has enormous potential to improve patient care, services and treatments and can only be done effectively if patients are given a say over how their personal information is used.</p><p> </p><p> </p><p> </p><p>The sharing of patient information, whilst protecting confidentiality, ensures the highest standards of care and clinical safety are consistently met throughout the National Health Service and where standards drop, allowing prompt action to be taken. It also helps to understand what happens to people, especially those with long term conditions, who are cared for away from hospital, and to ensure their needs are met and provides vital information needed to assist and support research into new medicines, and the better treatment of disease.</p><p> </p> more like this
answering member constituency Central Suffolk and North Ipswich more like this
answering member printed Dr Daniel Poulter more like this
question first answered
less than 2014-10-17T08:53:07.013Zmore like thismore than 2014-10-17T08:53:07.013Z
question first ministerially corrected
less than 2014-10-17T09:05:53.0362001Zmore like thismore than 2014-10-17T09:05:53.0362001Z
answering member
3932
label Biography information for Dr Dan Poulter more like this
previous answer version
22453
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
204
label Biography information for Paul Burstow more like this
92598
registered interest false more like this
date less than 2014-10-10more like thismore than 2014-10-10
answering body
Department of Health remove filter
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Medical Records: Databases more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what recent progress has been made on the care.data project; and if he will make a statement. more like this
tabling member constituency Sutton and Cheam more like this
tabling member printed
Paul Burstow more like this
uin 209877 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-17more like thismore than 2014-10-17
answer text <p>NHS England made an announcement on the progress of the care.data project on October 7.</p><p> </p><p> </p><p> </p><p>Further details can be found at:</p><p> </p><p> </p><p> </p><p>http://www.england.nhs.uk/2014/10/07/ccgs-care-data-programme/</p><p> </p> more like this
answering member constituency Central Suffolk and North Ipswich more like this
answering member printed Dr Daniel Poulter more like this
question first answered
less than 2014-10-17T08:57:51.97Zmore like thismore than 2014-10-17T08:57:51.97Z
question first ministerially corrected
less than 2014-10-17T09:05:37.2935139Zmore like thismore than 2014-10-17T09:05:37.2935139Z
answering member
3932
label Biography information for Dr Dan Poulter more like this
previous answer version
22454
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
204
label Biography information for Paul Burstow more like this